We are live on ! Find out more

West Pharmaceutical

WST

Market cap $24.6B

349.92 USD

+1.44

0.41%

At close Updated Aug 26, 4:00 PM EDT

Pre-market

After hours

349.92

0.00

0%

1 day

0.41%

5 days

0.21%

1 month

5.64%

3 months

10.67%

6 months

40.52%

Year to date

26.6%

1 year

43.12%

5 years

-21.67%

10 years

329.03%

About: West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Employees: 10,800

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 65.8%

Neutral 34.2%

Negative 0%

West to Participate in Upcoming Investor Conferences

EXTON, Pa., Aug. 26, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the following upcoming investor conferences: Wells Fargo Annual Healthcare Conference on Thursday, September 10, 2026 at 8:45 a.m. EDT in Everett, MA Morgan Stanley Annual Global Healthcare Conference on Monday, September 14, 2026 at 8:30 a.m.

West to Participate in Upcoming Investor Conferences

Zacks Investment Research

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

WST Stock Surges 38.1% Since March-End: What's Fueling the Rally?

Zacks Investment Research

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

Zacks Investment Research

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.

Should Investors Buy WST as HVP Growth Meets a Premium Valuation?

Zacks Investment Research

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

WST Q2 Beat and Raised 2026 Outlook Reinforce the HVP Growth Story

Zacks Investment Research

WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook

WST's HVP growth, wider margins and raised 2026 outlook support its recent rally, but a premium valuation raises the bar for further gains.

WST Gains 15.3% in Three Months as HVP Growth Strengthens Outlook

Conestoga SMid Cap Composite Q2 2026 Portfolio Review

West Pharmaceuticals stock moved higher following another quarter of broad-based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Tyler Technologies underperformed during the quarter despite delivering solid financial results that met management's guidance. We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.

Conestoga SMid Cap Composite Q2 2026 Portfolio Review

Best Dividend Aristocrats For August 2026

NOBL is outperforming SPY YTD in 2026, returning 12.9% versus SPY's 7.88%, with 45 Aristocrats ahead of SPY. Dividend growth among Aristocrats in 2026 averages 4.10%, with recent increases from ALB, FAST, PPG, SJM, and SWK. 25 Dividend Aristocrats appear undervalued and offer estimated long-term annualized returns of at least 10% using dividend yield theory.

Best Dividend Aristocrats For August 2026

West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.

West Pharmaceutical Delivers Another Beat - But The Real Story Is The Mix Shift

West Pharmaceutical Services Q2 Earnings Call Highlights

West Pharmaceutical Services NYSE: WST raised its full-year 2026 outlook after reporting second-quarter results that topped management's expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers.

West Pharmaceutical Services Q2 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™